Hunter’s syndrome mucopolysaccharidosis type II (MPS II) is a rare genetic disorder in which large sugar molecules called glycosaminoglycans (GAGs) or mucopolysaccharides are produced in body tissues. It is observed to be a form of lysosomal storage disease. Hunter’ssyndrome is caused by the deficiency of lysosomal enzyme iduronate-2-sulfatase (I2S). The lack of this enzyme causes heparan sulfate and dermatan sulfate to accumulate in all body tissues. Hunter’ssyndrome is the only MPS syndrome to exhibit X-linked recessive inheritance. The symptoms of this syndrome are abdominal hernias, ear infections, runny nose, and cold. As the buildup of GAGs continues throughout the cells of the body, signs of MPS II become more visible.
COVID-19 scenarioanalysis
Key pharmaceutical and biotechnological companies have grouped together with governments such that they meet the current demand for medical supplies throughout the globe.Increase in demand has been witnessed for drugs, which presentspotential opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs.There are around 115 vaccine candidates and other 155 molecules that are advanced such that the research and development pipelines are updated in the coming years. The commonly used drugs such as hydroxychloroquine have seenhugeboost in demand for the management of COVID-19.Due to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expectedto grow significantly in the coming years.
Top impacting factors: market scenario analysis, trends, drivers, and impact analysis
The major factor affecting the industry include introduction of novel therapies, which would propel the growth of the industry in the coming years.Increase in increase in government initiatives and rise in awareness about Hunter’s syndrome fuelthe market growth during the forecast period.In addition, surge in number of mergers and acquisitions boosts the market growth in the upcoming years. However, implementation of stringent regulations for the manufacturing of drugs may hinder the growth of the industry.
Surge in number of patients
According to the National MPS Society, Hunter’s syndrome is a rare condition affecting 1 in 100,000 to 1 in 170,000, primarily males.Females may be carriers of the gene for MPS II. Although rare, MPS II has been diagnosed in girls. If the mother is a carrier, there is a 50% chance that any boy born will have the disease.
Sisters and maternal aunts of a person with MPS II may be carriers of the disease and would also have a 50% chance of passing the syndrome to son.Increase in the of patient population would positively impact the growth of the industry in the near future.
Surge in number of mergers and acquisitions
Increase in the number of mergers and acquisitions is anticipated toboost the industrygrowth in the coming years. For instance, in July 2014, ArmaGen, a privately held biotechnology company, announced that it had entered into a worldwide licensing and collaboration agreement with Shire Plc.to develop AGT-182, an investigational enzyme replacement therapy (ERT) for potential treatment of both the central nervous system (CNS) and somatic (body-related) manifestations of Hunter’s syndrome.
In 2014, Shire agreed a deal to buy the U.S.Company, Lumena Pharmaceuticals for $260m, bolstering its pipeline of rare disease candidates. Shire had itself been the subject of merger speculation with Allergan. Furthermore, buying Lumena would help provide two drugs in mid-stage clinical trials for rare liver diseases that will complement its own gastrointestinal drug portfolio. LUM001 and LUM002 are both inhibitors of the apical sodium-dependent bile acid transporter, or ASBT, and are being tested as treatments for cholestatic liver diseases, which occur when the flow of bile from the liver to the duodenum is reduced or blocked. ASBT is responsible for recycling bile acids back to the liver.
Key benefits of the report:
- This study presents the analytical depiction of the global Hunter’s syndrome industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Hunter’s syndrome market share.
- The current market is quantitatively analyzed to highlight the Hunter’s syndromemarket growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the Hunter’s syndromemarket.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Hunter’s syndrome market research report:
- Which are the leading players active in the Hunter’s syndrome market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What are the projections for the future that would help in tasking further strategic steps?
Hunter’s Syndrome Market Report Highlights
| Aspects | Details |
 By Treatment Type |
|
 By Route of Administration |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Denali Therapeutics Inc.,, ArmaGen Inc.,, Inventiva S.A.,, GC Pharma,, Sangamo Therapeutics, Inc.,, JCR Pharmaceuticals Co Ltd.,, Regenxbio, RegenxBio Inc.,, Takeda Pharmaceutical Company,, Bioasis Technologies Inc. |
Loading Table Of Content...
